These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MR Imaging for Diagnosis of Malignancy in Mammographic Microcalcifications: A Systematic Review and Meta-Analysis.
    Author: Bennani-Baiti B, Baltzer PA.
    Journal: Radiology; 2017 Jun; 283(3):692-701. PubMed ID: 27788035.
    Abstract:
    Purpose To assess the use of magnetic resonance (MR) imaging for diagnosis of malignancy in lesions that manifest as microcalcifications at mammography. Materials and Methods Two independent readers performed a systematic review of the literature published as of February 1, 2016, by using predefined search terms. All studies in which contrast material-enhanced MR imaging was used for assessment of mammographic microcalcifications that were assigned Breast Imaging Reporting and Data System (BI-RADS) scores of 3-5 were deemed eligible. The standard of reference was established at clinical follow-up examination or histopathologic evaluation. Study design, technical parameters, number of true- and false-positive and true- and false-negative results were extracted to fit a cross-tabulation. Quality Assessment of Diagnostic Accuracy Studies-2 applet was used to probe for bias. Statistical analysis included data pooling, meta-regression, heterogeneity testing, and forest plot construction. Results Twenty studies met the inclusion criteria. These comprised 1843 lesions with a mean prevalence of malignancy of 40.6%. Bivariate analysis revealed pooled sensitivity and specificity of 87% (95% confidence interval [CI]: 81%, 92%) and 81% (95% CI: 75%, 86%) for all lesions, respectively; 95% (95% CI: 91%, 98%) and 61% (95% CI: 52%, 69%) for invasive lesions only, respectively; 57% (95% CI: 59%, 81%) and 32% (95% CI: 15%, 92%) for BI-RADS 3 lesions, respectively; 92% (95% CI: 85%, 96%) and 82% (95% CI: 74%, 88%) for BI-RADS 4 lesions, respectively; and 95% (95% CI: 87%, 99%) and 66% (95% CI: 26%, 92%) for BI-RADS 5 lesions. Diagnostic criteria other than presence of enhancement were inversely associated with sensitivity (P ≤ .013). Conclusion Breast MR imaging is not recommended for diagnosis of malignancy in BI-RADS 3 and 5 mammographic microcalcifications, but can be considered for BI-RADS 4 mammographic microcalcifications. The presence or absence of enhancement is the preferable diagnostic criterion to rule out malignancy in mammographic microcalcifications at breast MR imaging. © RSNA, 2016 Online supplemental material is available for this article.
    [Abstract] [Full Text] [Related] [New Search]